ASCO 2023: Record Numbers & the Big Show

The list ASCO released this week includes 30 SWOG-led abstracts, plus another 11 with significant SWOG representation/input (here’s the full list).

Here are the five SWOG oral presentations you’ll want to mark on your calendar, starting with the plenary talk. It’s a nice variety including a variety of effective treatments using different modalities, a discussion of toxicity, and even a presentation by one of our leading statisticians.

• “SWOG S1826, a Randomized Study of Nivolumab(N)-AVD versus Brentuximab Vedotin(BV)-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL)”
  Presenter: Alex Herrera, MD
• “SWOG S1011 - A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radial Cystectomy for Muscle Invasive Urothelial Cancer”
  Presenter: Seth P. Lerner, MD
• “Change in RECIST Tumor Size Correlates Linearly with Survival in Patients Treated with Checkpoint Inhibitor Therapy (SWOG S1609)”
  Presenter: Megan Othus, PhD
• “Chemotherapy Induced Peripheral Neuropathy (CIPN) due to Paclitaxel versus Docetaxel in Patients with Early-Stage Breast Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481)”
  Presenter: Meghna Trivedi, MD, MS
• “SWOG S1929: Phase II Randomized Study of Maintenance Atezolizumab (A) Versus Atezolizumab + Talazoparib (AT) in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)”
  Presenter: Nagla Abdel Karim, MD

Those five oral presentations will be complemented by 20 other SWOG-led abstracts presented in poster sessions (this list is ordered by trial number). Again, the variety is quite breath-taking:

• “Comparing the Prognostic and Predictive Utility of Serum Thymidine Kinase 1 and CA 15-3 in Patients with Hormone Receptor Positive Metastatic Breast Cancer Starting First-Line Endocrine Therapy in SWOG S0226”
  Presenter: Erin Cobain, MD
• “Adjusted Indirect Treatment Comparison of Progression-Free Survival (PFS) Associated with DRd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data”
  Presenter: Brian Durie, MD
• “Adjuvant Everolimus in Patients (Pts) with Localized Non-clear Cell Renal Cell Carcinoma (RCC): Subgroup Analysis from the EVEREST Trial (SWOG S0931)”
  Presenter: Shuchi Gulati, MD, MS
• “Baseline Circulating Tumor Cell (CTC) Count as a Prognostic Marker of Overall Survival (OS) in Metastatic Castrate Sensitive Prostate Cancer (mCSPC): Results from SWOG S1216, a Phase III Randomized Trial of Androgen Deprivation Plus Orteronel (CYP17 Inhibitor) or Bicalutamide”
  Presenter: Amir Goldkorn, MD
• “Bone Biomarkers and Subsequent Survival in Men with Bone-Metastatic Hormone Sensitive Prostate Cancer (HSPC): Results from the Phase III SWOG S1216 Trial of Androgen Deprivation +/- Orteronel”
  Presenter: Primo N. Lara, MD
• “Prostate-Specific Antigen at 3 & 7 months (PSA-3mo, PSA-7mo) Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Treated with Androgen Deprivation With or Without Orteronel (SWOG S1216)”
  Presenter: Mamta Parikh, MD, MS
• “Outcomes of African American (AA) versus Caucasian (CA) Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Treated with Androgen Deprivation Therapy (ADT) with or without Orteronel (O): Analysis of Patient-Level Data from the SWOG-1216 Phase 3 Trial”
  Presenter: Nicolas Sayegh, MD
• “Pathologic Concordance Rate and Outcomes by Histologic Subtype in Advanced Papillary Renal Cell (pRCC) Carcinoma: an Analysis from the SWOG S1500 (PAPMET) Trial”
  Presenter: Abhishek Tripathi, MD
• “Chemotherapy Dose Density is Prognostic for Patients with Resectable Pancreas Cancer: A Secondary Analysis of SWOG S1505”
  Presenter: Sameer Patel, MD
• “A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Vulvar Cancers”
  Presenter: Young Kwang Chae, MD, MPH, MBA
• “A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Desmoid Tumors (Cohort 27)”
  Presenter: Young Kwang Chae, MD, MPH, MBA
• “HERCULES: A Prostate Cancer (PC) Sequencing Panel for Parallel Analysis of Circulating Tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs) (SWOG S1802)”
  Presenter: Daniel Bsteh, PhD
• “ECOG-ACRIN LUNG-MAP S1900E Substudy (NCT04625647): A Phase II Study of Sotorasib in Participants (Pts) With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous (Non-sq) Non-Small Cell Lung Cancer (NSCLC)”
  Presenter: Sukhmani Padda, MD
• “A Phase III Randomized Trial of Eribulin (E) with or without Gemcitabine vs Standard of Care (SOC) for Metastatic Urothelial Carcinoma (UC) Refractory to or Ineligible for PD/PDL1 Antibody (Ab): SWOG S1937”
  Presenter: Sarmad Sadeghi, MD, PhD
• “A Randomized Phase 2 Trial of Encorafenib + Binimetinib +  Nivolumab vs Ipilimumab + Nivolumab in BRAFV600-Mutant Melanoma Brain Metastases: SWOG S2000 (NCT# 04511013)”
  Presenter: Zeynep Eroglu, MD
• “Randomized Phase II Trial of Olaparib + Pembrolizumab vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 (gBRCA1/2+) Mutations: SWOG S2001 NCT04548752”
  Presenter: Vincent Chung, MD
• “The Effect of ctDNA Tumor Fraction (TF) on Overall Survival and Concordance between Tissue Genomics and ctDNA in Lung-MAP”
  Presenter: Phillip C. Mack, PhD
• “Association of Baseline Measures of Socioeconomic Deprivation and Healthcare Utilization in Patients Enrolled in SWOG Cancer Clinical Trials”
  Presenter: Dawn Hershman, MD, MS
• “SWOG S1823/CCTG GCC1 - Translational Observational Investigational Study of the Liquid Biomarker microRNA 371a-3p in Newly Diagnosed Germ Cell Tumours - Real-World Trial Design, Rapid Accrual, and Robust Secondary Use of Data Opportunities”
  Presenter: Antoine Morin Coulombe, MD
• "Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials"
  Presenter: Joseph Unger, PhD

SWOG-led work accepted for ASCO includes an additional five publication-only abstracts, and SWOG researchers are contributors to 11 abstracts led by other groups.

If you can’t make it to Chicago for the show, watch this space for a date and time for our next “Best of SWOG at ASCO” webinar, which we’ll schedule for later in June.

The run-up to ASCO, not to mention the meeting itself, is always an exciting time. With the wealth of SWOG work to be presented, and expectations of a fabulous plenary presentation, this will be a June to remember!